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When chemicals pose a threat to human health, a theoretical safe dose 
for human exposure must be determined. This is the goal of chemical 
risk assessment in regulatory toxicology. Initially, animal toxicology 
studies are evaluated. Animal studies provide a means of predicting 
human toxicities when insu"cient human data is available.  
 
 
Di!erent regulatory bodies use di!erent approaches for inter-species 
dose extrapolation. This is where uncertainties arise. In our study, the 
extrapolation process used by the United States (U.S) Food and Drug 
Administration (FDA) and the European Food Safety Authority (EFSA) 
was compared. The FDA uses allometric scaling for chemical dose  
extrapolation, whilst the EFSA does not use allometric scaling. There-




Allometry can be de#ned as adjusting data to allow for di!erences in 
body size and function between species. (1) The FDA adjusts chemical 
doses according to the body surface area, in order to account inter-
species di!erences in metabolic rates. (2) However, drawbacks of  
allometry are also discussed in the literature. We aimed to discover 
whether the application of allometry to chemicals tested by the EFSA 
had the potential to a!ect regulatory decisions and, hence, determine the 
applicability of allometry to hazard characterization (dose-response  
relationship) in regulatory toxicology. 
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Methods 
 
The Committee on Toxicity (CoT) reviews EFSA toxicity data on 
chemicals in food, consumer products and the environment. (3) 
Chemical toxicity data was collected from open source CoT 
records, available at https://cot.food.gov.uk. Ethical approval was 
not required since the research project was limited to open source 
data. A total of 560 papers, from February 2008 to January 2020, 
were assessed in our study.  
 
 
The No Observed Adverse E!ect Level (NOAEL), animal species 
used, uncertainty factor, exposure assessment values (mean and 
97.5th percentile) were noted for each chemical found in the 
records. Chemicals were not included in our study if there were  
insu"cient information for analysis. Interestingly, some chemicals 
had multiple exposure assessment values, as multiple age groups 
were assessed. Therefore, 43 data points (chemicals with correspon-
ding exposure assessment age groups) were gathered in total.  
 
 
For each data point, doses were calculated with allometry using the 
FDA’s Maximum Recommended Starting Dose (MRSD) approach, 
and without allometry using the EFSA’s Health Based Guidance 
Value (HBGV) approach. (2,4) Absolute di!erences were calculated 
between doses with and without allometry. Absolute di!erences 
were then compared against exposure assessment values to assess if 
the data points were signi#cant. Ratios were calculated between 
doses with and without allometric scaling to assess the extent of the 
dose di!erence. An alpha of <0.05 was used to determine statistical 





Thirty-nine out of 43 data points had absolute di!erences greater 
than the mean exposure assessment values. Only 28 out of 43 data 
points had 97.5th percentile exposure assessment values quoted in 
CoT records. Of these 28 data points, 20 had absolute di!erences 
greater than the 97.5th percentile exposure assessment values. Over-
all, 20 data points had absolute di!erence greater than both the 
mean and 97.5th exposure assessment values. The absolute di!er-
ences for the 20 data points ranged from 2.364* 10^-5 to 2.097.  
 
 
Ratios, between doses with and without allometric scaling, ranged 
from 1.1 to 12.3. All 43 rations are shown on #gure 1. The largest 
dose decrease a$er allometry was approximately 92%, and was seen 
in bisphenol A, diethyphthalate, acetyl-deoxynivalenols and  
deoxynivalenols. A 9% dose decrease a$er allometry was seen in 
both zearalenone (in 4 to 12 month olds) and ochratoxin A (all age 
groups). However, the absolute di!erence of zearalenone was 
greater than both the mean and 97.5th exposure assessment values, 
wheres the absolute di!erence of ochratoxin A was not. 
The 95% con#dence interval of proportion between the total  
number of data points and signi#cant data points (when compared 





From the 95% con#dence interval of proportion calculated, It was 
evident that a majority of chemicals were a!ected by allometric 
scaling in our study. As shown by the data points “zearalenone (in 4 
to 12 month olds)” and “ochratoxin A (all age groups)”, it was also 
clear that similar dose decreases can lead to di!erent toxicological 
outcomes. Therefore, the signi#cance of allometry may not be 
down to the extent of the dose di!erence, but the chemical and/or 
age group itself.  
 
 
Published evidence by Schneider et al., also support the use of  
allometry in toxicological risk assessment. (5) However, based on 
our study alone, it is di"cult to conclude that allometric scaling 
alone could a!ect regulatory decisions. This is because our study 
contains some limitations and gaps in knowledge. For instance, 
only 43 data points were included in our study. Therefore, larger 
and in-depth studies are required to validate our #ndings. In the  
future, it may also be worth investigating intrinsic chemical properties, 
such as lipophilicity, to understand which chemicals are a!ected by 
allometry. In addition, physiologically-based toxicokinetic model-
ling could be utilised to identify the accuracy of allometry in future 
studies. (6)  
 
 
It is also important to note that allometry disregards many inter-
species variation, such as genetic polymorphisms a!ecting species’ 
toxicokinetics and toxicodynamics. (7) Therefore, allometry may 
not be reliable on its own. It may be that allometry should be used 
in combination with advancements in computational toxicology. 
This includes mathematically-modelled uncertainty factors or use 





Since allometric scaling is a concept dating back to 1930s, many  
papers had been published. Therefore, it was necessary to systemati-
cally evaluate older and recent publications. Formulating questions 
a$er reading the literature helped me conduct more focused data-
base searches and keep up with advancements in inter-species dose 
extrapolation. 
47
This data analysis project also involved evaluating many CoT papers. 
Hence, e!ective time management was of upmost importance.  
Setting myself deadlines every week and making daily “to-do” lists 
helped me keep up with the workload. Some mistakes were made 
when recording chemical data on Microso" Excel, which helped 
me realise the importance of proof reading with each data entry. 
Overall, this project challenged my critical thinking and organisa-
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